Conclusion Four completed trials now confirm retatrutide's efficacy across different populations, doses, and durations: Phase 2 (338 patients, 48 weeks): 24.2% proof of concept TRIUMPH-4 (445 patients, 68 weeks): 28.7% first Phase 3 confirmation TRIUMPH-1 (2,339 patients, 80 weeks): 28.3% pivotal confirmation in general obesity population TRIUMPH-1 extension (subset, 104 weeks): 30.3% weight loss continues beyond 80 weeks TRANSCEND-T2D-1 (537 patients, 40 weeks): 16.8% weight loss and -2.0% HbA1c in type 2 diabetes The consistency between TRIUMPH-4 (28.7%) and TRIUMPH-1 (28.3%) across two very different populations is the most important finding for obesity it means the results aren't driven by population-specific factors, they reflect the drug's fundamental mechanism
It is required in all living cells for the transport of fatty acids from the cytosol into the mitochondria during the breakdown of lipids (or fats) for the generation of metabolic energy
How Do Patients Experience This in Real Life
What makes this relevant to semaglutide users specifically
By adding glucagon agonism to the GLP-1/GIP foundation, Retatrutide creates a state where your body actively breaks down stored fat while simultaneously reducing caloric intake
Keep tirzepatide refrigerated between 36 and 46 degrees Fahrenheit (2 to 8 degrees Celsius)